Alligator Bioscience AB financials
Alligator Bioscience AB
549300E15VI0MB7LXV19 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Other income | SEK 1.9M | SEK 3.8M |
| Employee benefits expense | SEK 70.4M | SEK 79.4M |
| Operating profit (EBIT) | -SEK 229.1M | -SEK 249.0M |
| Net finance income / (cost) | -SEK 4.7M | SEK 397.0K |
| Finance costs | SEK 20.3M | SEK 1.4M |
| Profit before tax | -SEK 233.9M | -SEK 248.6M |
| Income tax expense | SEK 0 | SEK 0 |
| Profit for the year | -SEK 233.9M | -SEK 248.6M |
| Total comprehensive income | -SEK 233.9M | -SEK 248.6M |
| Per share | ||
| Basic EPS | SEK -0.32 | SEK -0.55 |
| Diluted EPS | SEK -0.32 | SEK -0.55 |
| Free cash flow / share | SEK -0.29 | SEK -0.42 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 212.4M | -SEK 189.3M |
| Income taxes paid | SEK 0 | SEK 0 |
| Net cash from investing activities | SEK 0 | -SEK 2.5M |
| Purchase of PP&E (capex) | SEK 0 | SEK 2.5M |
| Net cash from financing activities | SEK 211.3M | SEK 161.6M |
| Proceeds from borrowings | SEK 135.0M | SEK 0 |
| Lease liability payments | SEK 8.3M | SEK 9.8M |
| Net change in cash | -SEK 1.2M | -SEK 30.2M |
| Balance sheet | ||
| Total assets | SEK 104.3M | SEK 118.5M |
| Non-current assets | SEK 32.9M | SEK 40.3M |
| Right-of-use assets | SEK 1.3M | SEK 17.6M |
| Current assets | SEK 71.4M | SEK 78.2M |
| Trade & other receivables | SEK 518.0K | SEK 2.0K |
| Cash & equivalents | SEK 64.3M | SEK 66.1M |
| Total equity | -SEK 130.6M | SEK 11.9M |
| Non-current liabilities | SEK 33.5M | SEK 7.5M |
| Lease liabilities (non-current) | SEK 33.5M | SEK 7.5M |
| Current liabilities | SEK 201.5M | SEK 99.1M |
| Lease liabilities (current) | SEK 10.1M | SEK 8.6M |
| Derived metrics | ||
| Free cash flow | -SEK 212.4M | -SEK 191.7M |
| Operating margin | -396.7% | -428.5% |
| Net margin | -404.9% | -427.8% |
| Return on equity | 179.1% | -2096.9% |
| Cash conversion ratio | 0.91× | 0.76× |
| Capex coverage | — | -76.98× |
| Other reported items | ||
| Additional Paidin Capital | SEK 1.15B | SEK 1.06B |
| Adjustments For Decrease Increase In Trade and Other Receivables | SEK 4.9M | SEK 13.3M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | SEK 48.7M | SEK 10.5M |
| Adjustments For Increase Decrease In Trade and Other Payables | -SEK 34.3M | SEK 34.5M |
| Adjustments For Sharebased Payments | SEK 59.0K | SEK 74.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 183.0M | -SEK 237.0M |
| Computer Software | SEK 0 | SEK 15.0K |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 46.8M | SEK 66.0M |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 2.7M | SEK 7.5M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | SEK 48.7M | SEK 10.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -SEK 653.0K | -SEK 1.0M |
| Equity and Liabilities | SEK 104.3M | SEK 118.5M |
| Expense By Nature | SEK 288.9M | SEK 310.9M |
| Finance Income | SEK 15.6M | SEK 1.8M |
| Increase Decrease Through Conversion of Convertible Instruments | SEK 474.0K | — |
| Increase Decrease Through Exercise of Warrants Equity | SEK 1.1M | SEK 440.0K |
| Increase Decrease Through Sharebased Payment Transactions | SEK 59.0K | SEK 74.0K |
| Interest Paid Classified As Operating Activities | SEK 4.0M | SEK 483.0K |
| Interest Received Classified As Operating Activities | SEK 1.4M | SEK 1.9M |
| Issue of Equity | SEK 96.6M | SEK 195.1M |
| Issued Capital | SEK 607.0K | SEK 42.2M |
| Miscellaneous Other Operating Expense | SEK 2.5M | SEK 2.2M |
| Number of Shares Issued | 759.0M | — |
| Other Adjustments For Noncash Items | -SEK 70.0K | -SEK 1.0K |
| Other Comprehensive Income | SEK 0 | SEK 0 |
| Other Current Liabilities | SEK 140.6M | SEK 3.3M |
| Other Current Receivables | SEK 3.8M | SEK 4.5M |
| Other Expense By Nature | SEK 167.2M | SEK 218.8M |
| Other Noncurrent Receivables | SEK 2.1M | SEK 2.0M |
| Other Property Plant and Equipment | SEK 1.8M | SEK 2.7M |
| Par Value Per Share | SEK 0.00 | — |
| Payments For Debt Issue Costs | SEK 6.8M | SEK 0 |
| Payments For Share Issue Costs | SEK 7.5M | SEK 24.1M |
| Proceeds From Exercise of Warrants | SEK 977.0K | SEK 440.0K |
| Proceeds From Issuing Shares | SEK 97.1M | SEK 195.1M |
| Retained Earnings | -SEK 1.28B | -SEK 1.09B |
| Revenue and Operating Income | SEK 59.7M | SEK 61.9M |
| Revenue From Contracts With Customers | SEK 57.8M | SEK 58.1M |
| Share Issue Related Cost | SEK 7.5M | SEK 24.1M |
| Trade and Other Current Payables To Trade Suppliers | SEK 4.0M | SEK 21.3M |
Every line item above is a fact tagged in Alligator Bioscience AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.